Novartis Net Profit Boosted by Gain From Sandoz Spinoff — Update
By Adria Calatayud
Novartis reported a big jump in fourth-quarter net profit after it booked a gain from the spinoff of its generics-drugs business Sandoz.
Net profit for the fourth quarter was $8.48 billion compared with $1.47 billion in the same period a year before, the Swiss pharmaceutical major said Wednesday. This included a noncash gain of $5.9 billion from the distribution of Sandoz shares to Novartis shareholders that was completed in October, it said.
Net profit from continuing operations doubled to $2.64 billion on sales that rose 8% to $11.42 billion, Novartis said. Strong growth in sales of the company's Entresto heart drug and Cosentyx psoriasis treatment, with both topping $1 billion in quarterly revenue, helped the top line.
Core operating profit climbed 4.8% to $3.82 billion, it said.
Analysts polled by Visible Alpha expected Novartis to report fourth-quarter net profit of $3.75 billion on sales of $11.51 billion.
For 2024, the company said it expects growth in net sales of a mid single digit percentage and in core operating profit of high single digit, both at constant currency.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
January 31, 2024 01:40 ET (06:40 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks